Why HoLEP En Bloc is Superior to Turp for Large Prostates

For patients with prostates larger than 80 mL, transurethral resection of the prostate (TURP) has long been the standard surgical option. However, outcomes from over 10,000 procedures performed by Dr. Fernando Gómez Sancha at Instituto de Cirugía y Urología Avanzada (ICUA) Madrid demonstrate that Holmium Laser Enucleation of the Prostate (HoLEP) en bloc offers superior efficacy, faster recovery, and better long-term results.

Clinical Outcomes: Precision, Safety, and Efficacy

HoLEP en bloc achieves complete removal of the obstructing prostate tissue through precise laser dissection. Unlike TURP, which resects tissue in fragments, HoLEP enucleates the entire adenoma in one piece. This technique ensures more complete prostate clearance, particularly critical in glands exceeding 100 mL.

Studies from ICUA Madrid show a 98.7% success rate in complete tissue removal with HoLEP. In comparison, TURP achieves complete resection in only 82% of cases involving prostates over 80 mL. Intraoperative complications such as blood transfusions occur in less than 1.3% of HoLEP cases, versus 8.5% with TURP.

Postoperative urinary retention drops to under 2% with HoLEP, while TURP reports 5-7%. These outcomes reflect HoLEP's ability to deliver consistent, anatomically precise results regardless of prostate size.

Recovery Time and Patient Experience

Patients undergoing HoLEP en bloc experience significantly shorter catheterization and hospitalization times. At ICUA Madrid, the average catheter duration is 1.4 days post-HoLEP, compared to 3.8 days after TURP. Hospital stays average 1.8 days versus 3.2 days, respectively.

Early mobility and rapid symptom relief enhance patient satisfaction. Over 94% of HoLEP patients report substantial improvement in International Prostate Symptom Score (IPSS) within seven days. TURP patients reach similar scores in 14-21 days.

Key advantages include:

• Lower rates of postoperative bleeding (0.9% vs. 6.1%)
• Reduced need for bladder irrigation (1.1% vs. 9.3%)
• Earlier return to daily activities (median 5 days vs. 12)

These metrics highlight HoLEP's minimal invasiveness and superior tolerability, especially in elderly or comorbid patients.

Long-Term Results and Reoperation Rates

Durability is a critical factor in surgical decision-making. After 10 years, TURP shows a reoperation rate of 17-22% due to tissue regrowth or residual obstruction. HoLEP, by contrast, maintains a reoperation rate of just 2.4% over the same period.

The en bloc enucleation technique removes tissue at the surgical capsule, minimizing residual adenoma. This anatomical completeness reduces recurrence risk and preserves urethral integrity. Urodynamic studies at ICUA Madrid confirm sustained maximum urinary flow rates (Qmax) above 22 mL/s at five and ten years post-HoLEP.

Additional long-term benefits include:

• Stable International Index of Erectile Function (IIEF) scores
• Less than 1% incidence of urethral strictures
• No significant deterioration in continence over time

These outcomes establish HoLEP as the most durable surgical option for benign prostatic hyperplasia (BPH), particularly in large-gland cases.

Conclusion

HoLEP en bloc outperforms TURP in safety, recovery, and long-term efficacy for large prostates. With over 10,000 cases validating its success, the procedure represents the gold standard in advanced BPH surgery.